Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Alfuzosin Hydrochloride

FDA-approved product (tablet, extended release, oral), marketed as Alfuzosin Hydrochloride, Uroxatral.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Alfuzosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA50.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis41.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Alfuzosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Alfuzosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Multiple Dose, Bioequivalence Study of Generic Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets Under Fed Conditions

    NCT06316336 · start 2024-06-10

    Registered record
    Registry ID
    NCT06316336
    Conditions
    Healthy Vollunteer
    Interventions
    Alfuzosin Hydrochloride 10 mg; Xatral® XL 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-06-10
    Completion
    2024-06-28
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Vollunteer
    InterventionAlfuzosin Hydrochloride 10 mg; Xatral® XL 10 mg
    PhasePhase 1
    Registry statusUnknown

  • Alfuzosin and Mirabegron for Double-J Stent Symptoms

    NCT07018934 · start 2024-06-01

    Registered record
    Registry ID
    NCT07018934
    Conditions
    Ureteral Stent-Related Symptoms
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-06-01
    Completion
    2025-05-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUreteral Stent-Related Symptoms
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • The Bioequivalence Study of Alfuzosin 10 mg Prolong-released Tablets Under Fed Conditions

    NCT06228339 · start 2024-03-09

    Registered record
    Registry ID
    NCT06228339
    Conditions
    Healthy Volunteer
    Interventions
    Alfuzosin Hydrochloride 10 mg Prolonged-release Tablets; Xatral® XL 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Unknown
    Start
    2024-03-09
    Completion
    2024-03-21
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionAlfuzosin Hydrochloride 10 mg Prolonged-release Tablets; Xatral® XL 10 mg
    PhasePhase 1
    Registry statusUnknown

  • Intermittent Catheterization Versus Trial Without Catheter

    NCT05094947 · start 2021-08-03

    Registered record
    Registry ID
    NCT05094947
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    intermittent catheterization; trial without catheter; alpha-blockers
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2021-08-03
    Completion
    2022-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionintermittent catheterization; trial without catheter; alpha-blockers
    PhaseNot applicable
    Registry statusUnknown

  • The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil

    NCT03144596 · start 2015-10-29

    Registered record
    Registry ID
    NCT03144596
    Conditions
    Benign Prostatic Hyperplasia; Pupil Anomaly; Choroid Disease
    Interventions
    Alfuzosin Hydrochloride 10 MG; Tamsulosin Hydrochloride 0.4 MG
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-10-29
    Completion
    2016-11-19
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia; Pupil Anomaly; Choroid Disease
    InterventionAlfuzosin Hydrochloride 10 MG; Tamsulosin Hydrochloride 0.4 MG
    PhasePhase 4
    Registry statusCompleted

  • Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia

    NCT02977832 · start 2015-01

    Registered record
    Registry ID
    NCT02977832
    Conditions
    Benign Prostatic Hypertrophy With Outflow Obstruction; Benign Prostatic Hyperplasia
    Interventions
    Odyliresin; Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-01
    Completion
    2016-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hypertrophy With Outflow Obstruction; Benign Prostatic Hyperplasia
    InterventionOdyliresin; Alfuzosin
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions

    NCT01834729 · start 2013-03

    Registered record
    Registry ID
    NCT01834729
    Conditions
    Constipation
    Interventions
    Alfuzosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-03
    Completion
    2017-09-06
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionAlfuzosin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

    NCT01332487 · start 2010-08

    Registered record
    Registry ID
    NCT01332487
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-08
    Enrolment
    4,068

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

    NCT01435954 · start 2010-08

    Registered record
    Registry ID
    NCT01435954
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Early combination therapy; Delayed combination therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-03
    Enrolment
    13,551

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionEarly combination therapy; Delayed combination therapy
    PhaseNot recorded
    Registry statusCompleted

  • Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

    NCT01323998 · start 2010-04

    Registered record
    Registry ID
    NCT01323998
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    35,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; AB
    PhaseNot recorded
    Registry statusCompleted

  • Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use

    NCT01332435 · start 2009-11

    Registered record
    Registry ID
    NCT01332435
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-01
    Enrolment
    6,896

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms

    NCT00893113 · start 2009-06

    Registered record
    Registry ID
    NCT00893113
    Conditions
    Erectile Dysfunction; Lower Urinary Tract Symptoms
    Interventions
    Placebo; Alfuzosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-06
    Completion
    2012-10
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionErectile Dysfunction; Lower Urinary Tract Symptoms
    InterventionPlacebo; Alfuzosin
    PhasePhase 3
    Registry statusCompleted

  • Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence

    NCT01390870 · start 2009-05

    Registered record
    Registry ID
    NCT01390870
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI or AB or Combination Therapy (5ARI + AB)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI or AB or Combination Therapy (5ARI + AB)
    PhaseNot recorded
    Registry statusCompleted

  • Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment

    NCT01386983 · start 2009-03

    Registered record
    Registry ID
    NCT01386983
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; 5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-06
    Enrolment
    332

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; 5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • The Clinical Efficacy of Non-steroidal Anti-inflammation Drugs in Patients With Benign Prostatic Hyperplasia

    NCT00687388 · start 2008-05

    Registered record
    Registry ID
    NCT00687388
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    selective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    Interventionselective alpha 1-blockers; celecoxib; alpha-blocker and NSAID
    PhasePhase 4
    Registry statusWithdrawn